

All.Can at eight years Annual Report 2024

All.Can International is a not-for-profit organisation (ASBL) registered in Belgium.

Its work is made possible with financial support from Bristol Myers Squibb, Roche, MSD, Johnson & Johnson, Illumina, Amgen, BD, Astellas, Daiichi Sankyo, MNI, and EFPIA, among other funding means

Mission

All.Can is the global multistakeholder platform for cancer care efficiency, aiming to improve health outcomes for cancer patients around the world. We collaborate to advance efficiency in cancer care for the benefit of patients and society.

We do so by generating, promoting and advocating for evidence-based and measurable improvements in cancer care research, policy and practice.

Vision

We imagine a world in which patients are always at the heart of cancer care. We work together for efficient, equitable and sustainable cancer care that focuses on what matters to patients and society.

All.Can's work is guided by three Key Principles:



Put patients first Define and deliver cancer care efficiency according to what matters most to patients and society.



Adopt a wholesystem perspective Eliminate inefficiencies across the entire cancer care pathway and spectrum.



Promote multistakeholder collaboration Harness the strengths of all cancer care stakeholders.

Contents

Foreword	4
All.Can Key Achievements in 2024	6
Advancing Cancer Care Efficiency: Key Milestones and Strategic Actions from All.Can International in 2024	7
Strengthening Partnerships for Greater Impact in Cancer Care	10
Advocating for Holistic, Efficient, and Equitable Cancer Care: Endorsements and Contributions	11
Highlights of All.Can participation at events in 2024	12
Members	13
National Initiatives	14

All.Can International is a not-for-profit organisation (ASBL) registered in Belgium.

Its work is made possible with financial support from Bristol Myers Squibb, Roche, MSD, Johnson & Johnson, Illumina, Amgen, BD, Astellas, Daiichi Sankyo, MNI, and EFPIA, among other funding means.

Foreword

As we reflect on 2024, All.Can proudly marks its 8th year and steps confidently into its role as a leader in advocating for efficient cancer care. With five years as an officially recognised not-for-profit association, we continue to uphold our mission of enhancing health outcomes for individuals impacted by cancer across the globe through policy research and strategic advocacy.

Our commitment remains focused on fostering accessible, patient-centred, evidence-based, high-quality care. By doing so, we aim to ensure the best possible outcomes and experiences for everyone touched by cancer.

At the heart of All.Can is a spirit of community. This year has been especially significant for engaging and collaborating with our partners across the cancer landscape. Together, we strive to drive progress toward adaptive and learning healthcare systems, ensuring the equitable use of resources now and in the future.

- In 2024 All.Can finalised the development of the Action Guide for Efficient Cancer Care: An implementation toolkit, in collaboration with the Academic Medical Centre of the University of Amsterdam (AMC). The guide is All.Can's latest publication; it showcases best practices in the field of efficient cancer care in Greece, Switzerland, Canada, Australia, and Mexico, amongst others, by shining a light on the most impactful projects, looking throughout the care pathway.
- All.Can's Global Summit took place on 16 September in Geneva, Switzerland. The event, held prior to the opening of the UICC World Cancer Congress, was

attended in person and virtually by close to 200 participants from 40 countries across all stakeholder groups — patient organisations, healthcare professionals and clinicians, data experts, industry and health system decision-makers.

- The All.Can National Initiatives global network launched various new and creative projects, including All.Can Canada's focus on improving equitable cancer care and enhancing Alberta's breast cancer diagnostic pathway by cutting wait times by 50%; All.Can Colombia's completing its Second Grand Survey with 1,200 patients; and All.Can Germany's strides forward in aligning its national cancer plan with the EU Beating Cancer Plan.
- Our partnerships and collaborations have been crucial in incorporating All.Can's definition of cancer care efficiency and evidence-based recommendations into major projects and initiatives. These efforts include a webinar series co-hosted with the SPCC and the rollout of EU cancer screening programs in six EU countries, in partnership with the EFPIA Oncology Platform Screening Programs: Spain, Italy, Belgium, Romania, Poland, Sweden. All.Can was actively engaged in the EU-funded projects 4P-Can and SmartCARE, for which we lead the 4P-Can work package on policy recommendations. All.Can was active in Mission Early - advancing early cancer detection and care, involved in an OECD working group and WHO submission on NCDs, not to mention ongoing partnerships with the EAVH, UICC, and EUHC. Numerous other collaborations are underway, detailed within this report.

All.Can's strategic goals remain clear: advancing thought leadership, facilitating meaningful dialogues and policies, and enhancing systems and pathways both globally and locally.

With a collective commitment to shaping policy and improving treatment efficiencies, the projects, collaborations and on-going discussions with All.Can's stakeholders, including its members and National Initiatives, continue to lay the groundwork for impactful changes within the cancer care community as we look ahead to 2025.



All.Can Key Achievements in 2024



50k

Website visits

Advancing Cancer Care Efficiency: Key Milestones and Strategic Actions from All.Can International in 2024

The year 2024 was marked by key milestones that enhanced All.Can's reputation as well as its commitment to improving efficiency in cancer care worldwide.

All.Can International is active in two EU-funded consortia projects: 4P-CAN and SmartCARE. These projects mark a significant milestone for the organisation, strengthening its engagement with European stakeholders while furthering its mission to improve cancer care efficiency.

The 4P-CAN Consortium Meeting on 8 April, hosted at the WHO European Union Office, facilitated strategic discussions on project progress, collaborative planning, and innovative approaches to cancer prevention. The meeting underscored the importance of public health partnerships and the integration of policy and research efforts to enhance prevention strategies across Europe. On 9 April, All.Can took part in the European Parliament event Cancer Primary Prevention: Main Risk Factors in Europe, **Regulations, Implementation Level, and Future Steps**. This high-level discussion highlighted the role of the 4P-CAN project in addressing modifiable cancer risk factors, bringing together policymakers, researchers, and health advocates. The agenda featured policy insights on the Mission on Cancer, updates on 4P-CAN's research outcomes, and recommendations for future action. Through 4P-CAN and SmartCARE, All.Can is actively shaping the future of cancer prevention, survivorship, and healthcare efficiency, reinforcing its position as a driver in evidence-based advocacy and policy transformation

Ahead of its official launch at the All.Can Global Summit in September, the Action Guide for Efficient Cancer Care was pre-launched during the EU Health Policy Platform (EUHPP) live webinar, hosted by the European Commission,

"Unveiling the Efficiency Path in Cancer Care: A Step-by-Step Guide", held on 25 April 2024. This EU HPP webinar provided a crucial platform for early insights into the Action Guide, offering new evidence and guidance on integrating efficiency metrics into cancer care pathways at both the European and global levels. The webinar also highlighted key recommendations from the Action Guide, demonstrating how efficiency measures can be applied in real-world settings.

The General Annual Meeting, held online on **29 April**, provided an opportunity for the organisation's membership to reflect on its achievements from the past year, discuss governance matters and share updates on ongoing projects.

One of the defining moments of the year was the All.Can Global Summit 2024, which took place on 16 September in Geneva with over 70 participants in-person and a similar number online. This high-level summit, with experts from different countries around the world, served as a unique platform for exchanging



Chief Executive Officer, Eduardo Pisani speaks at the All.Can Global Summit 2024

Geneva, 16 November

participants in person

)+ 70+ participants online



Launch of the Action Guide for Efficient Cancer Care: An Implementation Toolkit

All.Can Global Summit 2024 Geneva, 16 November "The All.Can Global Summit 2024 in Geneva was a pivotal event, uniting global leaders in the cancer community to share innovative strategies for enhancing cancer care efficiency. Launched at the Summit, All.Can's Action Guide for Efficient Cancer Care provides a structured framework for healthcare systems to optimise resources and prioritise patient outcomes for a better quality of life."

Christobel Saunders All.Can International VP and President-Elect



ideas and strategies for making cancer care more efficient. Discussions focused on prevention and screening to reduce the cancer burden, early detection to improve treatment success, personalised treatment approaches for better patient outcomes, and holistic, integrated care to ensure comprehensive patient support and improved quality of life.

Ultimately, the summit marked the launch of All.Can's latest milestone — *the Action Guide for Efficient Cancer Care: An Implementation Toolkit* — which offers a structured framework to help healthcare systems implement efficiency metrics in a way that prioritises **patient outcomes and resource optimisation**. The guide, which was developed in collaboration with the University of Amsterdam's Medical Centre (UMC), emphasises that efficiency in cancer care is not just about cost reduction but about making the most of available resources — **personnel, finances, technology, and infrastructure** — **to improve the quality of care and the patient experience**. All.Can International's Action Guide for Efficient Cancer Care received significant visibility through key publications and media features in 2024, highlighting its impact on advancing efficiency in cancer care. On December 23, the Euractiv Advocacy Lab published an article titled "Roadmap to Improved EU Cancer Care Efficiency Emerging, New Study Points the Way", analysing the Action Guide's role in shaping policy discussions. On September 25, OncoDaily covered the All.Can Global Summit, featuring the launch of the Action Guide and its potential to drive change worldwide. Cancerworld, on October 3, summarized key findings from the Efficiency Metrics study, reinforcing the importance of data-driven approaches in cancer care. Additionally, on **December 16**, the All.Can Action Guide was published in the Journal of Cancer Policy, further solidifying its role as a reference tool for policymakers, healthcare professionals, and stakeholders committed to improving cancer care efficiency.

As part of its efforts to support the widespread adoption of efficiency measures, All.Can launched the *Communications and Engagement Toolkit* to accompany the *Action Guide*. This toolkit was developed to assist National Initiatives in promoting and disseminating the key recommendations from the implementation toolkit. It includes stakeholder mapping, template narratives, letters for engaging journalists and policymakers, guidance for drafting policy briefs and conducting briefing sessions, and organising one-on-one meetings with key decision-makers.

To facilitate effective use of the toolkit, All.Can hosted **two webinar series**, guiding participants through its contents and offering practical insights on how to engage with healthcare providers, policymakers, and patient organisations. These sessions addressed common questions and provided hands-on strategies for leveraging the toolkit to drive meaningful action in various countries.



Cancer Care Efficiency through Personal ...

by AllCan International

Playlist • Public • 5 videos • 2 views

Through a series of interviews, All.Can aims to capture the perspectives of cancer patients and clinicians,more



Cancer Care Efficiency videos

Conversations with patients and healthcare professionals.

Beyond formal reports and policy toolkits, All.Can International closed 2024 with a strong **focus on digital advocacy** by launching a series of insightful conversations with patients and healthcare professionals, shedding light on realworld challenges and opportunities in achieving more efficient, patient-centred cancer care. These digital storytelling efforts helped translate the principles of the *Action Guide for Efficient Cancer Care* into relatable, real-world insights, making efficiency in cancer care a tangible and accessible concept for a broader audience. The campaign provided a powerful foundation for continued engagement into 2025.

Looking toward 2025, All.Can will focus on key initiatives to advance efficiency in cancer care. This includes the implementation of the Action Guide for Efficient Cancer Care, with pilot projects in three countries and targeted outreach to key stakeholders. Additionally, efforts will be strengthened around personcentred cancer care pathways through a study on health systems transformation focusing on patient access and lost patients, alongside an advocacy campaign to drive policy change.

All.Can will also play a leadership role in EUfunded consortia on cancer prevention and literacy, contributing to 4P-CAN by shaping policy recommendations for primary prevention and leading CURTAIN in developing a database of resources to educate the public and policy action recommendations on cancer literacy in Europe. Beyond these, partnerships and collaborations will expand, including further leveraging the Efficiency Hub and collaborating with the EFPIA on the implementation of EU cancer screening recommendations.

For further information or to explore ways to support these initiatives, please contact the **All.Can Secretariat at <u>secretariat@all-can.org</u>.**

Strengthening Partnerships for Greater Impact in Cancer Care

One of the most significant policy initiatives in which All.Can was actively involved was the **EFPIA Oncology Platform (EOP) project**, which began in **May 2023 and will continue into 2025**. This initiative, launched in collaboration with the **EFPIA Oncology Platform**, aims to promote a constructive, evidence-based dialogue on the implementation of the updated EU Cancer Screening Recommendation adopted in December 2022 as part of Europe's Beating Cancer Plan.

The first phase of the EOP project (May 2023 -April 2024) focused on Belgium, Italy, Romania, and Spain, engaging national stakeholders through policy dialogues, roundtables, research to assess cancer policy frameworks, raising awareness of the EU Cancer Screening Recommendation, and exploring national implementation pathways. Building on these insights, the second phase (May 2024 - April **2025)** is expanding efforts to new countries while continuing work in Italy and Spain. The focus in Italy (Piemonte and Puglia) and Spain (Basque Country and Galicia) shifts to regional screening implementation. In Poland, the project will leverage its EU Council Presidency to advance national screening policies, while in Sweden, efforts will align with the upcoming National Cancer Plan revision to integrate lung and prostate cancer screening.

On **19 January 2024**, All.Can International participated in **the WHO-led stakeholder dialogue** for the development of the **Global Cancer Status Report 2025**. This informal consultation, coordinated by the WHO HQ Cancer Team, gathered insights from global stakeholders, UN agencies, and non-State actors to define the scope, methodology, and key priorities of the upcoming report. The *2025 Report on Cancer* aims to provide a comprehensive assessment of global cancer control efforts, tracking progress based on established indicators, policy initiatives, and national strategies.

The collaboration with **Sharing Progress in Cancer Care (SPCC)** established a framework for institutional partnership and project cooperation, ensuring that both organisations could align efforts to maximise impact and drive positive change in healthcare. As the partnership progressed, updates on joint initiatives were shared, highlighting how the combined expertise of All.Can and SPCC contributed to improving efficiency and outcomes in cancer care.

All.Can supported **Digestive Cancers Europe** (**DiCE**) during **European Colorectal Cancer Awareness Month (ECCAM) 2024**. Held in March 2024, this awareness campaign featured a walkathon designed to promote prevention and early detection of colorectal cancer. The initiative sought to mobilise communities, encourage healthy lifestyle choices, and reinforce the importance of screening programs in reducing colorectal cancer cases.

> "All.Can places a strong emphasis on strategic collaborations that integrate our shared vision for efficient cancer care and evidence-based strategies into impactful EU projects, such as supporting the implementation of the updated EUwide cancer screening recommendations. By collaborating with entities like EFPIA and engaging in initiatives such as the WHO-led Global Cancer Status Report 2025, All.Can is helping shape cancer policy across numerous countries to the benefit of patients."



Martin Whalen, Senior Vice President, Global Policy & International Government Affairs, BMS

Advocating for Holistic, Efficient, and Equitable Cancer Care: Endorsements and Contributions

A key development was All.Can's engagement in the Fourth High-level Meeting of the UN General Assembly on the Prevention and Control of Noncommunicable Diseases (NCDs) in May 2024. As part of the webbased consultation for the WHO-Director General's report, All.Can provided policy recommendations and insights on cancer care efficiency, integrated care models, the role of digital solutions, and health system sustainability. All.Can's contributions in particular underscored the importance of efficiency as a lever to achieve Sustainable Development Goal (SDG) 3.4 — to reduce premature mortality from NCDs by onethird by 2030.

Recognising the vital role of nutrition in cancer care, All.Can endorsed the **Medical Nutrition International Industry (MNI) Manifesto**, which aligns with its position on integrated multidisciplinary care. The endorsement is rooted in findings from All.Can's **2019 patient survey**, where **24%** of respondents reported a lack of access to support from allied health professionals, including dietitians.

All.Can also endorsed a report from the European Collaborative Action on Medication Errors and Traceability (ECAMET) and the EAASM. This report highlighted the dangers posed to cancer patients due to inadequate resources and staffing shortages, emphasising the severe consequences of workforce deficits in complex medical treatment settings such as oncology. As part of this initiative, All.Can co-signed the report's foreword alongside leading organisations such as the ECAMET Alliance, EHMA, and ESNO, urging EU institutions to prioritise workforce solutions in healthcare legislation.

All.Can was also among the key stakeholders consulted for the OECD's report *Beating Cancer Inequalities in the EU – Spotlight on Cancer Prevention and Early Detection.* This comprehensive report examined global disparities in cancer care, with a particular focus on inequalities related to region, socioeconomic status and gender. It provided an analysis of cancer incidence and mortality trends across Europe, highlighting persistent gaps in access to early detection and treatment.

As a partner organisation, All.Can International was also proud to contribute to the latest report by the European Alliance for Value in Health, titled A Compass for Collaboration: Navigating Stakeholders' Roles in Transitioning to Value-Based Healthcare. This report provides a comprehensive framework for defining stakeholders' roles in accelerating the shift toward value-based health systems, emphasising the need for collaboration, efficiency, and patient-centred care.

"A long-term vision is needed to implement VBHC. We need to ensure measurement of patientrelevant outcomes, ensure payment is linked to value and outcomes and ensure integration across the full cycle of care – all underpinned by strong collaboration between stakeholders"

Eduardo Pisani All.Can International

A Compass for Collaboration

OECD Health Policy Studies

Beating Cancer Inequalities in the EU SPOTLIGHT ON CANCER PREVENTION AND EARLY DETECTION

European Cancer Inequalities Registry

Beating Cancer Inequalities in the EU

OECD report, All..Can was key stakeholder

European Alliance for Value in Health report 11

Highlights of All.Can participation at events in 2024:

11 January 2024 All.Can Poland Annual Event – Eduardo Pisani

2-4 February 2024 **the 8th Annual Congress of the Hellenic Cancer Federation (ELLOK)** – Matthew Hickey and Madalina lamandei

8 April 2024 **4P-CAN Consortium Meeting** – Eduardo Pisani and Madalina lamandei

9 April 2024 Cancer Primary Prevention: Main Risk Factors in Europe, Regulations, Implementation Level, and Future Steps – Eduardo Pisani and Madalina lamandei

25 April 2024 EUHPP Live Webinar on "Unveiling the Efficiency Path in Cancer Care: A Step-by-Step Guide – Ana Sofia Carvalho

29 August 2024 All.Can Mexico Symposium – Ana Sofia Carvalho

17-20 October 2024 National Cancer Conference BJCN-MORE 2024 – George Kapetanakis and Eduardo Pisani 23 October 2024 ICHOM Leadership Forum on Value-Based Healthcare - Eduardo Pisani, Ebba Hallersjö, and Matt Hickey

5-6 November 2024 Digital Health Society Summit 2024 – Prof. Christobel Saunders, Matt Hickey, Alex Filicevas and Eduardo Pisani

19 November 2024 Roundtable Discussion for Stronger EU Early Cancer Care Policies at the European Parliament – Eduardo Pisani

20-21 November 2024 European Cancer Summit 2024 – Sofia Carvalho

4 December 2024 **The European Cancer Forum** – Eduardo Pisani

5 December 2024 **"Let's Talk Prostate Cancer" Roundtable at the European Parliament** – Eduardo Pisani

Members

All.Can International's membership reflects its multi-stakeholder representation and includes experts from patient organisations, policymakers, healthcare professionals, researchers and industry. Its 34 organisational and ten individual members contribute their unique knowledge and expertise to improve efficiency in cancer care, act as ambassadors for All.Can, and help to publicise its work, events, publications and research findings. Our members act as champions for All.Can International, advocating for beneficial changes in policy and practice through evidence-based policy research and best practice dissemination. Members align with the All.Can's vision and goals, particularly in advancing efficient cancer care and practices. Members not only have a national but also an international focus, including efforts directed towards low-income nations.

We welcomed three new organisational members in 2024:



Bulgarian Joint Cancer Network (BJCN). Established in 2021, the Bulgarian Joint Cancer Network (BJCN) is a non-governmental non-profit association with public benefit activities. In social terms, it is an open cluster organization, that functions as an ecosystem of medical and non-medical societies with a wide range of multidisciplinary interrelations in the field of oncology.



Global Coalition for Radiotherapy (GCR). The

Hellenic Cancer Federation (ELLOK), founded in 2016, is a patient-led non-profit organization with 49 members of Cancer Patient Associations, representing various cancers and regions of the country, with a comprehensive understanding of the diverse landscape of cancer care in Greece. The organisation's overarching aim is to realize a vision of comprehensive, timely, and affordable cancer care for all patients.



Hellenic Cancer Federation-ELLOK (Greece). The Hellenic Cancer Federation (ELLOK). founded in 2016, is a patientled non-profit organization with 49 members of Cancer Patient Associations, representing various cancers and regions of the country, with a comprehensive understanding of the diverse landscape of cancer care in Greece. The organisation's overarching aim is to realize a vision of comprehensive, timely, and affordable cancer care for all patients.

National Initiatives

By the end of 2024, All.Can proudly recognised 21 countries that have launched multistakeholder National Initiatives, tailoring the All.Can mission to local contexts and advancing its objectives.

Throughout 2024, All.Can National Initiatives have worked diligently to unite stakeholders, identify healthcare system needs and challenges, develop

policy recommendations and advocate for their inclusion in national cancer plans and policies.

These Initiatives have shared their experiences, achievements and best practices through regular meetings of the All.Can National Initiative Working Group, as well as via the All.Can International website, newsletter and social media.

Some highlights include:

All.Can Greece actively improved cancer care through initiatives such as a white paper on a National Cancer Care Plan, webinars, surveys, KOL roundtables, research on patient quality of life, digital tools and biomarker integration discussions, and adapting the Action Guide for Efficient Cancer Care.





All.Can Korea enhanced psychological support for cancer patients by establishing self-help groups and developing comprehensive "Guidelines for Self-help Groups for Psychological Support of Cancer Patients," emphasising emotional support and collaboration.



In 2024, it engaged with political leaders, organised cancer screening seminars, and presented reports including "Cancer has No Waiting Time. 10 recommendations for improvement: from diagnosis to treatment." It plans new actions for 2025 including expanding its member network to enhance the patient experience.










All.Can Norway focused on patientcentred cancer care, hosting a debate on "prehabilitation" during <u>Arendal Week</u> involving a Parliament representative, a health authority representative, as well as researchers to emphasise the importance of exercise. All.Can Norway prioritises "Reliable & Safe Discharge" and "Prehabilitation" to improve patientperceived quality of care.



All.Can Israel's inaugural conference, held in Israel, gathered oncology experts, patient advocates, and policymakers to address significant issues in cancer care. Emphasising teamwork and innovation, the event included 20 roundtable discussions on themes such as patient involvement, early diagnosis, and fair access to healthcare. Notable results included suggestions for a Patient Navigator role, organising a cancer app hackathon, and establishing a multisector coalition to promote enduring improvements in cancer care.

All.Can National initiatives bring the All.Can mission into a local context. They work to identify the needs of their specific healthcare systems and implement solutions in national cancer plans and policies.



All.Can Argentina

Achievements in 2024

The focus in 2024 was to relaunch and reposition All.Can as a key policy initiative in Argentina. In this regard, we implemented a series of roundtables for Board Members to outline training sessions on key topics such as cancer navigation and communication, among others. Additionally, we developed detailed reports on public sector stakeholders to define an engagement plan aligned with our strategic policy framework. We also published two policy landscapes that reflect the collaboration among All.Can Argentina members and developed a research paper on the role of caregivers and the situation of informal carers in Argentina, with a specific focus on those supporting people living with cancer.

To keep Board Members informed, the All. Can Argentina Secretariat launched a weekly newsletter providing updates on the regulatory landscape, political situation, and the evolution of the public health policy agenda. Furthermore, as part of our strategies to strengthen patient associations and their advocacy capabilities, we organized a roundtable to discuss potential initiatives in the field of blood cancer.

The All.Can activities in 2024 played a key role in building and strengthening relationships with key cancer decision-makers in Argentina, positioning BMS as a trusted partner in the cancer policy space. These efforts have provided deeper insights into the healthcare ecosystem, allowing us to identify key stakeholders for collaboration and further strengthen our Coalition. They have also enabled us to refine our public affairs and communication strategies based on a better understanding of stakeholders, while enhancing the visibility and long-term sustainability of All. Can Argentina.





All.Can Australia

Achievements in 2024

All.Can Australia focused on updating and refining its 2018 patient survey in collaboration with the Oncology Industry Taskforce. This effort involved revising the survey questions to better capture the challenges currently faced by Australians affected by cancer. To ensure that the findings would provide meaningful insights, the organisation partnered with an academic fellow to develop a structured framework for analysing the results.

Alongside this project, All.Can Australia played a key role in the newly established Cancer Nursing and Navigation Working Group, an initiative led by the Australian government. Leveraging its prior experience in developing a cancer care navigation model, the organisation contributed to discussions on improving the program's data architecture. These efforts aimed to create a more structured approach to tracking patient navigation outcomes and ensuring consistency in data collection across the country.

Throughout the year, All.Can Australia also explored issues related to medication use and availability for cancer patients. By assessing drugrelated efficiencies and potential shortages, the organisation began laying the groundwork for future initiatives that could help optimise access to essential treatments. captures relevant Australian data and highlights the most pressing issues affecting those diagnosed with cancer.

A key priority will be the continued development of data architecture for the Cancer Nursing and Navigation Program. By creating a structured framework to consistently track patient navigation data nationwide, All.Can Australia aims to support a data-driven approach that enhances the effectiveness of cancer care services. This work will continue within the Cancer Nursing and Navigation Working Group, focusing on ensuring the program's successful implementation and long-term impact.

Another major focus for 2025 will be addressing the efficient use and availability of medications for cancer patients. Efforts will be directed toward identifying ways to optimise drug use, reduce inefficiencies, and mitigate medication shortages that may impact patient care. These initiatives will contribute to a broader strategy aimed at improving access to essential treatments and ensuring that cancer patients receive the care they need without unnecessary delays.

Through these efforts, All.Can Australia remains committed to improving cancer care by addressing patient needs, strengthening datadriven decision-making, and advocating for policy changes that enhance service efficiency across the healthcare system.



All.Can Belgium

Achievements in 2024

All.Can Belgium made significant strides in advancing cancer care. A notable achievement was the organisation of the conference titled *Cancer Care: the Future is Now* on 6 November 2024 in Brussels. This event convened leading medical experts and policymakers to discuss the evolving landscape of oncology in the 21st century. Key topics included the impact of innovation on healthcare organisations, the role of artificial intelligence in cancer care, and the integration of digital technology to support patients and healthcare providers.

In light of the Belgian elections, All.Can Belgium published a memorandum and call to action, outlining key priorities to improve cancer care.

Additionally, All.Can Belgium actively advocated for the implementation of a national lung cancer screening program. On 16 December 2024, the organisation called upon policymakers to consider such a program, emphasising that it could save lives and is supported by both scientific evidence and public backing.

The organisation also launched a lung cancer awareness campaign, *Clear the Air on Lung Cancer*, aimed at exposing myths and taboos surrounding the disease. A highlight of the campaign was a public event at Central Station in Brussels. The campaign successfully reached 3 million people, raising awareness and encouraging open dialogue about lung cancer.

Outlook for 2025

Looking ahead to 2025, All.Can Belgium plans to build upon its previous initiatives to further enhance cancer care efficiency and patient outcomes. The organisation intends to implement the insights gained from the conference *Cancer Care: the Future is Now* by focusing on the readiness to innovate, improving access to innovative treatments, and ensuring that healthcare systems stay abreast of advancements so patients can fully benefit.

A strategic board meeting was scheduled for December 2024, where key decisions were to be made to shape the organisation's priorities and projects for 2025. The focus will be on prevention and early detection, defining clinically meaningful objectives in oncology therapy evaluation, translating the recommendations of the Optimoc project into feasible actions, and continuing efforts to enhance the preparedness and readiness of all stakeholders for innovation in cancer care—because the future is now.





All.Can Canada

Achievements in 2024

In 2024, All.Can Canada continued to work toward optimising people's entry into cancer care through swift, accurate, and appropriately delivered diagnosis.

In January 2024, All.Can Canada hosted the Optimizing Cancer Diagnoses in Canada Roundtable. This event consisted of two days of dialogue: one devoted to Indigenous leadership in health and cancer care, and the other to racialised, LGBTQ+, and other structurally underserved groups. Following the event, All.Can Canada published two 'What We Heard' reports outlining the learnings from the meetings along with next steps.

- ROUNDTABLE REPORT: Optimizing Equitable
 <u>Cancer Diagnosis with First Nations Inuit</u>
 <u>and Métis Communities Roundtable:</u>
 <u>What We Heard</u>
- ROUNDTABLE REPORT: <u>Optimizing</u> <u>Equitable Cancer Diagnosis for Structurally</u> <u>Underserved Communities Roundtable: What</u> <u>We Heard</u>

One of these next steps was revising All.Can Canada's Current State of Cancer Care - Patient Experience Map, which depicts the current state of cancer diagnosis in a dizzying infographic full of twists and turns. The updated <u>Current State of</u> provincial stakeholders, particularly in Alberta, Nova Scotia, and Prince Edward Island, and at the national level with organisations such as the Canadian Partnership Against Cancer.


They also produced two new practice case studies:


- CASE STUDY #5: <u>Alberta Breast Cancer</u> <u>Diagnostic Assessment Pathway</u>
- CASE STUDY #6: <u>PAROLE-Onco (English)</u>

Outlook for 2025

In 2025, All.Can Canada will:

- Develop/identify and spread symptom pathways to support primary care providers' ability to refer for cancer investigation in an expedited fashion.
- Create new practice case studies while continuing to share and encourage use of their existing case studies.
- Continue to share the equity related findings from the Optimizing Cancer Diagnoses in Canada Roundtable.
- Launch All.Can Canada's new proprietary website.
- Support the Connected Care for Canadians Act through participation in the Healthy Data Collective and the Canadian Institute of Health Information's Health Data Standards.





Cancer Diagnosis in Canada includes the numerous barriers that underserved populations and First Nations, Inuit, and Métis (FNIM) communities experience when trying to interact with the healthcare system.

All.Can Canada continued to build their relationships with

All.Can Colombia

Achievements in 2024

In 2024, All.Can Colombia focused on two major initiatives aimed at improving cancer care efficiency. The first was the socialisation of its second large-scale patient survey, which gathered insights from 1,200 patients. This study sought to assess the experiences and challenges faced by cancer patients in Colombia, providing valuable data to inform future healthcare policies and initiatives.

Alongside this, All.Can Colombia launched an applied cancer efficiency project in collaboration with the National Cancer Institute. This project is centred on the development of facial prostheses, ensuring that their construction aligns with efficiency metrics to improve accessibility and quality for patients in need. By integrating these efficiency principles, the initiative aims to optimise resources while maintaining high standards of patient care.

Outlook for 2025

In 2025, All.Can Colombia will continue to build upon these foundational efforts, with a strong focus on three key priorities: advancing the applied cancer efficiency project, socialising findings on efficiency metrics and strengthening international collaborations. The applied cancer efficiency project will move into its implementation phase, with ongoing support to ensure its success. Regular meetings with All.Can International will be held to align the project with global developments in cancer efficiency and metrics.

A major initiative for the year will be the continued socialisation of the efficiency metrics study. This will involve engaging with key stakeholders, including members of the All.Can Colombia coalition, experts from the University of Amsterdam, and representatives from the national health sector. These discussions will help translate research findings into actionable improvements in cancer care.

All.Can Colombia also aims to strengthen its coalition and expand relationships with other international initiatives. This effort will include fostering closer ties with global partners to exchange best practices and enhance Colombia's approach to cancer care efficiency. Through these initiatives, All.Can Colombia remains committed to driving innovation, improving patient outcomes, and contributing to a more efficient and effective oncology landscape in Colombia.





All.Can Germany

Achievements in 2024

In 2024, All.Can Germany focused on two key initiatives aimed at improving cancer care and policy development. The first was the continuation of patient-oriented support throughout the cancer life cycle, particularly by engaging pharmacies in providing guidance and assistance to cancer patients. This effort sought to ensure that patients received adequate information and support at various stages of their treatment and recovery.

At the same time, All.Can Germany actively contributed to the renovation of the National German Cancer Plan. In alignment with the EU Beating Cancer Plan, the organisation engaged in dialogue with policymakers to advocate for necessary updates and improvements. A major milestone in this effort was the discussion with staff of key organizations in cancer care, concerned representatives of the federal ministry of health and Members of Parliament on 13 November, where progress toward an advanced version of the National Cancer Plan was reported and evaluated.

Outlook for 2025

In 2025, All.Can Germany will continue to play a key role in shaping the new version of the National German Cancer Plan, with particular attention to optimising care during the patient care pathway. By ensuring that these critical phases receive enhanced support, the organisation aims to improve the overall efficiency and effectiveness of cancer care.

Another major priority will be strengthening collaborations with various national NGOs engaged in cancer-related initiatives. By fostering stronger networks among different organisations, All.Can Germany hopes to drive greater synergy and coordination in efforts to improve patient outcomes and streamline healthcare services.

Additionally, the organisation will focus on supporting innovative cancer-related projects backed by the German Innovation Fund. These projects aim to introduce new approaches to cancer care and treatment, enhancing both efficiency and patient well-being. While the connection between these initiatives and the All.Can *Efficiency Action Guide* and Health Services Research in Germany is still under evaluation, All.Can Germany remains open to integrating these frameworks to maximise impact.

Through these efforts, All.Can Germany will continue advocating for policy improvements, fostering cross-sector collaboration, and supporting innovation in cancer care to ensure that patients receive the best possible support throughout their journey.



All.Can Greece

Achievements in 2024

In 2024, All.Can Greece made significant progress in cancer research, policy advocacy, and international collaboration. A major milestone was the publication of the research study *Quality of Life for Cancer Patients in Greece* in March. Conducted in collaboration with Professor Ioannis Yfantopoulos, a leading expert in health economics at the University of Athens, and the All.Can Greece Steering Committee, this study provided crucial insights into the experiences and satisfaction levels of cancer patients in Greece.

All.Can Greece, together with All.Can International participated in the 8th Annual Conference of the Hellenic Cancer Federation in a roundtable entitled "Standardisation, recording & utilisation of efficiency indicators in oncological care". During the roundtable, progress on the Action Guide for Efficient Cancer Care: An implementation toolkit was presented to the Greek audience for the first time. Furthermore, Professor Ioannis Yfantopoulos presented the findings of the Quality of Life for Cancer Patients in Greece research.

On the global stage, All.Can Greece participated in the All.Can International Global Summit in Geneva on 16 September. During this event, George Kapetanakis, President of the Hellenic Cancer Federation and a member of the All.Can Greece Steering Committee, highlighted the challenges faced by Greek cancer patients, the impact on their quality of life, and the broader social and economic repercussions of a cancer diagnosis.

Another critical initiative was a stakeholders' roundtable entitled "Biomarkers: Co-creating the Framework" held in Athens on 6 November. This event brought together policymakers, healthcare professionals, researchers, and industry representatives to develop a structured plan for introducing and reimbursing biomarkers testing in Greece. The roadmap, presented by Aris Angelis, General Secretary of the Greek Ministry of Health, outlined a systematic approach for evaluating, pricing, and integrating biomarkers into the national healthcare system, ultimately aiming to enhance clinical effectiveness and economic efficiency.

Outlook for 2025

In 2025, All.Can Greece will focus on building upon the foundations laid in 2024 to further enhance cancer care efficiency and policy development. One of the main priorities will be the widespread dissemination of the *Action Guide for Efficient Cancer Care*, which was translated into Greek in 2024. This guide will be distributed to key cancer care and health policy stakeholders across Greece and presented at major oncological conferences throughout the year.

Additionally, All.Can Greece will continue to advocate for improved patient access to precision medicine, ensuring that the roadmap for biomarker integration moves forward in collaboration with policymakers and healthcare institutions. Strengthening stakeholder engagement and driving policy implementation will be critical to making meaningful progress in this area.

Through these initiatives, All.Can Greece remains committed to improving the quality of life for cancer patients by advancing efficiency in oncology care, fostering international collaborations, and driving evidencebased policy changes to benefit the Greek healthcare system.





Ποιότητα ζωής καρκινοπαθών με τη χρήση του EQ-5D-5L και EORTC-QLQ-C30

All.Can Israel

Achievements in 2024

All.Can Israel made significant strides in 2024 by launching a dedicated website designed to serve as a centralised resource for oncology patients. This platform brings together public, private, and nonprofit sectors to ensure that every cancer patient, regardless of their stage in the journey, has access to reliable information, relevant organisations, and essential tools to navigate their care. Inspired by the simplicity and accessibility of platforms like Booking.com or Airbnb, the website consolidates fragmented information into one user-friendly space, eliminating barriers to access and making oncology resources more readily available to those in need.

Another major milestone was Israel's successful first national conference for cancer organisations on March 27, 2023. This landmark event gathered 247 participants from 118 organisations, including hospitals, public institutions, nonprofits and private companies, to address gaps and challenges in cancer care. Through structured roundtable discussions, stakeholders collaborated to identify key issues and develop cross-sector solutions.

Following the conference, All.Can Israel established several task forces focused on addressing critical areas in oncology care. These included increasing the role of family doctors in early cancer detection, creating a national knowledge centre for patient engagement, developing certification programs for workplaces promoting early detection, and establishing oncology patient councils to influence policy. Other initiatives aimed at caregiver empowerment, automatic access to patient rights, survivorship support, and advancing integrative oncology approaches.

Throughout the year, All.Can Israel conducted multiple meetings to refine the objectives of these

task forces, ensuring that their work aligns with patient needs and healthcare system priorities. After thorough discussions with the board, three main areas of focus were identified as top priorities for further development: survivorship, patient rights, and reducing healthcare inequities.

Outlook for 2025

In 2025, All.Can Israel will build on the strong foundation laid in the previous year by expanding its impact in three key areas: survivorship, patient rights and healthcare equity. These priorities reflect the most pressing needs identified through the national conference and subsequent stakeholder engagements.

One major initiative will be further strengthening survivorship support through the introduction of a "Survivor Code". This framework aims to establish survivorship as a recognised field of expertise, granting cancer survivors structured access to dedicated services and benefits that address their unique, long-term needs.

Ensuring that patients receive automatic and proactive access to their rights will also be a major area of focus. By working closely with policymakers and healthcare institutions, All.Can Israel aims to integrate a system within the healthcare framework that guarantees patients receive the benefits and entitlements they qualify for without unnecessary bureaucratic hurdles.



All.Can Italy

Achievements in 2024

In 2024, All.Can Italy made significant progress in advancing cancer screening programs and aligning them with European recommendations. Efforts focused on improving the effectiveness and accessibility of these programs to ensure they met established standards. Additionally, research was conducted on the development and application of CAR-T cell therapy in select Italian regions, revealing governancerelated challenges. These findings provided a foundation for future improvements and policy development, marking a critical step forward in addressing gaps in cancer care and treatment.

Outlook for 2025

Looking ahead to 2025, for the time being the organisation will prioritise two key areas. First, efforts will focus on expanding and structuring cancer screening networks at the regional level to enhance coordination, coverage and efficiency. Second, building on the 2024 CAR-T therapy research, a structured pathway will be developed in collaboration with platform partners to address governance limitations and establish policy guidelines for its effective implementation. Moreover, the organisation is trying to prioritise other macro issue considering the interest expressed by different players working in the field of health in Italy. In particular: risk stratification and bringing non-intensive care oncology care closer to the patient on the ground, moving out of the hospital care setting. Overall, 2025 will be a year of strategic expansion and policy-driven improvements in cancer care.





All.Can Mexico

Achievements in 2024

In 2024, ongoing projects focused on supporting research investment and strengthening the position of All.Can Mexico. Key initiatives included delivering results from research on the indirect costs incurred by caregivers of 10 cancer types, with findings presented at the ISPOR World Congress. Additionally, intervention strategies were designed to reduce the time to treatment initiation for breast cancer patients at INCan, with final results expected by Q4. The implementation of a Hospital-Based Cancer Registry at INCan also progressed significantly. Efforts to strengthen All Can Mexico's position involved developing strategic messages on social networks, launching a local communication campaign and producing a series of podcasts featuring relevant cancer stakeholders. Strategic links were also established with key players, including researchers, clinicians and NGOs through mapping and alliance-building activities.

Outlook for 2025

In 2025, priorities will centre on supporting research investment, strengthening All.Can Mexico's position, and leveraging evidence to influence policy. The organisation will present findings from studies on indirect costs and breast cancer care timing to inform the new Mexican government's Health Sector Program. Efforts will also focus on building efficiency metrics, such as time to diagnosis and time from tissue diagnosis to treatment, in collaboration with INCan. Strategic communication campaigns and partnerships with key stakeholders, including researchers, clinicians and NGOs will continue to expand All.Can Mexico's influence. New projects include launching the third All.Can Award call, disseminating the Action Guide and study results, and contributing to INCan's Intrahospital Registry to support the National Cancer Registry. These initiatives aim to enhance cancer care efficiency and policy development in Mexico.





All.Can Norway

Achievements in 2024

All.Can Norway experienced significant impact in 2024, as they were able to reap the fruits of many years of efforts to put "prehabilitation" on the agenda in the Norwegian cancer debate.

The Norwegian Directorate of Health has now announced that prehabilitation will be included as part of cancer treatment in the upcoming national cancer strategy.

Since its launch, All.Can Norge has had "Reliable & Safe Discharge" and "Prehabilitiation" as the two key areas of focus – summarised by the steering committee as "patient-perceived quality". Already in 2018, pre-launch, All.Can Norway, together with Aktiv mot kreft, presented a report during the political Arendal Week documenting the social value of exercise for people affected by cancer. At the political week in August 2024 All.Can Norway and Aktiv mot kreft collaborated on a large and important debate on "prehabilitation". Participants includes a parliamentary representative who is also a member of the health committee from the governing party, another from the national health authority and two researchers from one of the country's largest hospitals, Bärum Sykehus. In addition, the patient voice was clearly represented. Here it became clear that the majority now agrees that prehabilitation must be included as part of the Norwegian cancer strategy.

With this important milestone All.Can Norway has increased its leverage within the Norwegian Cancer Policy debate.



All.Can Poland

Achievements in 2024

In March 2024, All.Can Poland published the report *Diagnosis of Changes in Oncology and Haemato-Oncology Care in 2023"* which analyses yearly achievements in oncological and haemato-oncological care, pointing out challenges and unmet needs.

In November 2024, All.Can Poland published the report Barriers to Access Innovative Treatment in Selected Cancers (lung and renal cancer)". The report, developed in cooperation with IQVIA, presented barriers in access to diagnostics and innovative treatment, along with recommendations for changes necessary to improve equal access for all patients across Poland. The report was presented at a press conference.

Both reports were distributed to influential policymakers, such as officials from the Ministry of Health, the National Health Fund, the Agency for Health Technology Assessment and Tariffication and the Polish Parliament Health Committees.

In mid-2024 we joined the EFPIA in a project to promote EU Oncological Screening Recommendations in Poland. We established a working group and gathered a data for the opening report.

Outlook for 2025

In February 2025 All.Can Poland published and medialise the report Oncological Screening Programs being the result of continued project started in 2024. All.Can Poland, together with Rynek Zdrowia - the most influential portal organised the debate with the participation of experts and representativea of Parliament and National Health Fund. Meetings are planned with parliamentarians and the Ministry of Health, as well as the presentation of the report during system congresses.

In March All.Can Poland plans to release and medialise the report *Diagnosis of Changes in Oncology and Haemato-Oncology Care in 2024*.

Alongside these reports, All.Can Poland will maintain active online engagement through our website and social media channels such as Facebook, X and LinkedIn to share reports, offer insights on key developments, and promote cancer prevention education.



8 listopada 2024 r.

All.Can Romania

Achievements in 2024

All.Can Romania's efforts in 2024 brought key stakeholders together and succeeded in keeping cancer issues on the public agenda against the backdrop of a challenging political landscape of democratic forces countering extremism.

After achieving significant milestones and creating a noteworthy impact in its inaugural year (2023), All.Can Romania's strategy in 2024 focused on resource efficiency, the main goal being to streamline both the patient journey and the appropriate use of available resources for the care of oncological and onco-haematological patients in Romania.

The local initiative acted as a catalyst platform, bringing together technical oncological expertise within the Romanian healthcare system. As our purpose in 2024 was to come up with a solid plan for increasing resource efficiency in Romania's oncology system, we had an external expert in macroeconomic public politics focused on the health sector collect and analyse the available data.

Preparing the resource efficiency draft plan and integrating input from contributing members were followed by a preparatory technical debate involving All.Can Romania members, sponsor allies and scientific partners, with the contribution of technical staff from the Ministry of Health, the Ministry of Finance, the National Health Insurance House and the National Institute of Health Services Management. The results of the analysis were formally shared with All.Can Romania members during a wrap-up event in December.

The discussions during the preparatory technical meeting in November proved to be extremely useful and were unanimously appreciated by the

experts present. Since the debate could not be concluded at the time, discussions continued in a restricted format with experts from the Ministry of Finance and the National Institute of Health Services Management. As 2024 was a very complicated year in terms of political decisions, these technical meetings were crucial to progress with achieving our impact goals.

The inclusion of additional partners — the National Society for Medical Oncology (SNOMR) as a scientific partner and Rayscape, an AIpowered radiology software for medical imaging analysis, as a sponsoring partner— was also a huge step ahead in our striving to consolidate our positioning as a platform for key stakeholders in the cancer domain in Romania.

Outlook for 2025

In 2025, All.Can Romania will keep its focus on enhancing the resource efficiency in Romania's oncology system by disseminating key recommendations of the analysis concluded in 2024, fostering stakeholder engagement, ensuring implementation, and enhancing public awareness and support. While collaborating with All.Can global network, All.Can Romania remains committed to elevate the local initiative to become a trusted and valuable resource in oncology and onco-hematology, ultimately transforming cancer care in Romania.



All.Can Spain

Achievements in 2024

In 2024, All.Can Spain carried out important events, all of them focused on detecting inefficiencies in the oncology care circuit and improving the care of cancer patients. Some of these events were:

Cancer Screening Summit: at the end of February, the national chapter of the platform organised an event at the European Commission headquarters in Madrid, in collaboration with the EFPIA and Astellas Spain. The summit, titled New Horizons in Cancer Screening in Europe, focused on the exchange of information on cancer screening in Spain. All.Can Spain presented the ten principles established by its Scientific Committee on early detection programs, developed after a meeting with WHO expert Isabel Mosquera-Metcalfe. During the roundtables the importance of early detection of cancers such as lung, prostate and gastric cancer was discussed, with an emphasis on improving diagnosis and reducing mortality rates. .

One to One Meetings with Parliamentary Groups' Health Representatives: All.Can Spain held a series of one-to-one meetings with different parliamentary groups' health representatives. The main objective of these meetings was to present the platform's second report, Cancer Does Not Understand Waiting Times. 10 Recommendations for Improvement:



From diagnosis to treatment. Impressions and relevant information on the report's contents were exchanged during these meetings, simultaneously providing a space to hear the parliamentarians' opinions of the proposed recommendations.

Appearance of All.Can Spain before the Health Commission of the Congress of Deputies:

Report on waiting times in oncology. As a continuation of the dissemination of the second report, the Scientific Committee of All.Can Spain appeared before the Health Commission of the Congress of Deputies. During the appearance, special emphasis was placed on the importance of the time involved in the process of cancer diagnosis and treatment; the report's ten recommendations to reduce waiting times and improve the quality of life of patients; and the need to address the healthcare system's current inefficiencies so as to achieve a more efficient and equitable care circuit.

Promotion of a Parliamentary Initiative in

Congress: on 4 November, All.Can Spain presented a joint parliamentary initiative proposal to the Congress of Deputies of nine key points to transform cancer care in Spain. The proposal arose in response to the growth in the incidence of cancer, which in 2023 became the leading cause of death in Spain. During the event, members of the All.Can Scientific Committee emphasised the need to prioritise public policies that optimise care processes, from diagnosis to treatment, and to improve access to innovative therapies. The creation of quality indicators and the improvement of training for health professionals were also proposed.

Debate in Galicia on cancer screening: On 19 December, All.Can Spain, in collaboration with the Galician Ministry of Health, organised a workshop session on the challenges and opportunities of new cancer screening programs according to European recommendations.

All.Can Sweden

Achievements in 2024

In 2024, ongoing projects included collaborating with All.Can Sweden and the EFPIA on the implementation of the EU Cancer Screening Recommendation. A report is currently being developed to serve as the foundation for three roundtable discussions focused on lung cancer and prostate cancer screening. Additionally, efforts continued to address the measurement and follow-up of cancer care to promote greater equality. Planning is underway for 2025 activities, including participation in Vitalis and Almedalen, two key platforms for decision-making in Sweden. These initiatives aim to ensure Sweden remains aligned with EU recommendations and advances in cancer care.

Outlook for 2025

In 2025, priorities will focus on three key areas. First, the collaboration with international partners and the EFPIA will drive efforts to advance cancer screening and ensure Sweden keeps pace with EU recommendations. This will include finalising the report and hosting three roundtable discussions. Second, participation in Vitalis, Sweden's largest e-health conference, will highlight the importance of measurement and follow-up in cancer care. Third, engagement at Almedalen, Sweden's largest political arena, will provide an opportunity to discuss strategies for creating more efficient and equitable cancer care, including a planned breakfast seminar on inequality in cancer care.

New for 2025 is a focus on ensuring that all patient groups, particularly young cancer patients, are included in discussions about measurement and data. Collaborating with members Barncancerfonden and Ung Cancer, All.Can Sweden aims to raise awareness and address the unique needs of younger patients, ensuring their voices are heard in the broader conversation about cancer care equality and efficiency. These efforts reflect a commitment to inclusive and impactful cancer care initiatives.



All.Can Switzerland

Achievements in 2024

In 2024, significant progress was made thanks to the creativity and passion of their members. A key achievement was the establishment of a baseline for understanding the situation of cancer survivors in Switzerland. This foundational work has paved the way for targeted projects aimed at improving the lives of those affected by cancer. Building on this study, Switzerland initiated the development of a guideline on survivorship care in collaboration with the Swiss Group for Clinical Cancer Research (SAKK). This guideline focuses on interdisciplinary cooperation among specialists and addresses various aspects of survivorship care. All.Can Switzerland is grateful to the JAKA Foundation for its financial support of this crucial project.

Additionally, they had the privilege of supporting the formation of SwissCAPA, a new association of oncology patient organisations, marking a meaningful step forward in patient advocacy and collaboration.

Prof. von Moos from Chur Cantonal Hospital has shown in a study, which was supported by All.Can Switzerland, that Nurse-Led Consultations (NLC) could make oncological care more efficient. The model increases patient satisfaction, shortens waiting times and involves nursing staff more closely. In economic terms, the costs per patient can be reduced if doctors can concentrate on more complex cases. Although the medical workload remains high, the greater responsibility makes the nursing profession more attractive - a promising approach for overburdened healthcare systems. NLC can be a cost-effective model, especially in overburdened healthcare systems and shortages of specialised staff.

Outlook for 2025

Looking ahead to 2025, their focus will be on implementing survivorship care guidelines by establishing the necessary structures and processes. This will involve working closely with healthcare professionals and stakeholders to ensure the guidelines are integrated effectively into practice. They will also continue to support and collaborate with SwissCAPA as it grows and strengthens its role in representing oncology patient organisations. These efforts reflect the commitment of All.Can Switzerland to improve cancer care and support for survivors, fostering collaboration, and driving meaningful change in the Swiss healthcare landscape.



Join us. Work with us. Together, we All.Can.

All.Can International Rue du Luxembourg 22-24 BE-1000 Brussels Tel: +32 2 761 66 73 secretariat@all-can.org www.all-can.org



All.Can

@AllCanGroup

All.Can International is a not-for-profit organisation (ASBL) registered in Belgium.

Its work is made possible with financial support from Bristol Myers Squibb, Roche, MSD, Johnson & Johnson, Illumina, Amgen, BD, Astellas and MNI, among other funding means.



Changing cancer care together